Pay in 4 interest-free payments of $7.16 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
The "minimal initial benefit" group (approximately 5-10% of users) reported limited improvements during treatment making discontinuation effects irrelevant, typically explained by inadequate product quality with degraded or low-concentration GHK-Cu, inappropriate application technique reducing absorption, unrealistic expectations exceeding what any topical can achieve, severe underlying pathology requiring medical intervention beyond cosmetic peptides, or individual non-responsiveness to copper peptide treatment for genetic or physiological reasons
We will let you know once we are ready for you to enter
Subsequently, they received intravenous injections of PBS, Ru(II)-OH, NP2, or NP4 (at a dosage of 2 mg/kg Ru) on days 0, 3, 6, and 9, respectively
Front Genet 13:845747
